Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Xuesaitong Soft Capsule in Acute Coronary Syndrome After PCI
NCT06618495Phase 2Completed
- Sponsor
- Xiyuan Hospital
- Start
- Dec 2024
- Primary completion
- Nov 2025
- Modality
- PE (Plant Extract)
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of xuesetong capsule in acute coronary syndrome (ACS), sponsored by Xiyuan Hospital. Primary endpoints: Transcriptome analysis of patients' platelets at 4 weeks, Metabolomics analysis of patients' platelets at 4 weeks and 1 more. Started Dec 2024; status: completed.
02
Drugs
xuesetong capsule
03
Conditions
acute coronary syndrome (ACS)
Beyond the preview
Go deeper on NCT06618495.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06618495.